AKT1 and rheumatoid arthritis: The effects are presumably caused by the activation of the PI3K/AKT signaling pathway by miR-26a-5p, which occurs by targeting the 5′UTR of PTEN. Therefore, miR-26a-5p is a suitable clinical target for developing innovative therapeutic methods for RA [64].